Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

iseases, including SJIA[5]. ACZ885 works by neutralizing IL-1 beta for a sustained period of time, therefore inhibiting inflammation.

ACZ885 is currently approved in the US and other countries for a different disease state.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "can," "on track," "potentially," "will," "planned," "may," "committed," "potential," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for ACZ885 or regarding potential future revenues from ACZ885. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with ACZ885 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that ACZ885 will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that ACZ885 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding ACZ885 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; unexpected manufacturing issues, the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Navitas, a leading Regulatory Service provider, today announced that ... in Bogota, Colombia . Navitas, expansion into ... by Colombia , the third largest economy in ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... clients to communicate with Navitas regulatory professionals in close to or the ...
(Date:7/3/2015)... Texas (PRWEB) , ... July ... ... biotechnology company providing industry-leading products for use in applications such as animal ... in wastewater treatment plants and restaurant kitchen settings, announced today that it ...
(Date:7/3/2015)... , ... July 03, 2015 , ... The global failure ... 7.52% from 2015 to 2020. The bioscience market is expected to grow at the ... use of failure analysis equipment in the research labs and academic institutions for root ...
(Date:7/3/2015)...  Pomerantz LLP announces that a class action lawsuit ... the "Company")(NYSE: PBYI ) and certain of its ... Court, Central District of California , ... class consisting of all persons or entities who purchased ... 2015 inclusive (the "Class Period").  This class action seeks ...
Breaking Biology Technology:Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3DryLet to Highlight Benefits of Patented ManureMagicâ„¢ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4
... Aug. 20 GSI Group Inc.,(Nasdaq: GSIG ) ... the tender offer by its indirect wholly-owned subsidiary Eagle,Acquisition ... of,Excel Technology, Inc. (Nasdaq: XLTC ). The initial ... City time, on Tuesday, August 19,2008., The depositary ...
... Strategic Fit with Lilly,s Animal Health Division, GREENFIELD, ... and Company (NYSE: LLY ), today announced that ... to the dairy cow supplement,Posilac(R) (sometribove), as well as ... )., "Global dairy demand is increasing, outstripping supply, ...
... has selected OpenClinica as its electronic data capture (EDC) and ... , ... Ruetlingen, Germany (PRWEB) August ... has selected OpenClinica as its http://www.openclinica.org/section.php?sid=1 [electronic data ...
Cached Biology Technology:GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period 2GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period 3Elanco Announces Acquisition of Posilac(R) Dairy Business 2Elanco Announces Acquisition of Posilac(R) Dairy Business 3OpenClinica EDC Solution Deployed for Retina Implant Studies 2OpenClinica EDC Solution Deployed for Retina Implant Studies 3
(Date:6/16/2015)... /CNW Telbec/ - handyem Inc. and FlowMetric Diagnostics ... of handyem,s HPC-150 portable flow cytometer within FlowMetric ... unprecedented model of mobile laboratory platform is presented ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue of ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
(Date:6/15/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... announces that its leading payment security technology, the Wocket® smart ... NYC June 18th. Digital Experience! @ NYC is ... to over 300 of the top media covering the sector. ... New York City from 6:00 to ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... 2012 In a study published in the March ... Academy of Child and Adolescent Psychiatry , Katherine Rice ... of Atlanta, and Emory University School of Medicine, used ... social disability in children with autism spectrum disorders (ASD) ...
... team of researchers show that most neandertals in Europe died ... a Europe populated by a stable neandertal population for hundreds ... therefore be revised. This new perspective on the ... in Molecular Biology and Evolution . The results indicate ...
... PHOENIX, Ariz. Feb. 27, 2012 The 9th ... pancreatic cancer research at the Translational Genomics Research Institute ... will go toward new international clinical trials run by ... first time that major retailers, producers and suppliers in ...
Cached Biology News:Eye-tracking reveals variability in successful social strategies for children with autism 2European Neandertals were on the verge of extinction even before the arrival of modern humans 2Celebrity Golf Classic raises $553,443 for Seena Magowitz Foundation 2
SDS-OutT SDS Precipitation Reagent...
... Sciclone inL10 Workstation from Caliper represents a ... for the first time the ability to ... react to changing conditions. In addition, ... viscosity due to changes in temperature, and ...
... The Staccato Series of systems ... for today's drug discovery, genomics, proteomics ... are available in three base configurations; ... Custom Systems Series. All Staccato ...
... on over 20 years of experience in ... Life Sciences, the Freedom EVO platform delivers ... according to future needs. Together with the ... is equipped to successfully operate genomics, proteomics, ...
Biology Products: